OptimizeRx (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced on [date] that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility comprises a $25 million term loan and a $10 million revolving credit facility, which was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction.
This credit facility provides OptimizeRx with additional financial flexibility to execute its strategic growth plans, including investments in its AI-driven platform and expansion of its market reach. The company's platform combines innovative tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement between life science brands and healthcare providers (HCPs) and patients.
The announcement underscores OptimizeRx's commitment to redefining how life science brands connect with patients and HCPs. By bridging the gap between HCP and DTC strategies, the company empowers brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. The new credit facility is expected to support these efforts, enabling OptimizeRx to scale its operations and enhance its technology offerings.
For more details on the announcement, visit https://ibn.fm/G0Fj3. OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies, using privacy-safe, patient-centric technology to make a meaningful impact. Headquartered in Waltham, Massachusetts, the company is dedicated to transforming the healthcare landscape.
The $35 million credit facility comes at a time when the healthcare technology sector is experiencing rapid growth, driven by increasing demand for digital health solutions. OptimizeRx's focus on AI-driven engagement tools positions it well to capitalize on this trend. The facility provides a solid financial foundation for the company to pursue its objectives without diluting shareholder equity.
Investors and industry observers will likely view this move as a positive signal of OptimizeRx's financial health and growth prospects. The undrawn revolving credit facility offers additional flexibility for future needs. As the company continues to innovate and expand its platform, the credit facility will support its mission to deliver life-changing therapies to the right patients at the right time.
